Cells were infected at low multiplicity to achieve one copy of GFP7 per cell, sorted for GFP-positive cells, and split into two parallel populations at the time of sorting. After 3 weeks of growth, cells were selected with blasticidin (not shown) to remove cells with transcriptionally silent GFP7 after which GFP-negative cells were sorted. Vector integration site libraries were prepared from the unsorted (Total) and GFP-negative (GFP-) populations using HTISA method to assess the frequency of individual integration sites in the population. (B) Numbers of GFP7 vector integration site sequence reads from each integration site obtained by HTISA sequencing of a mix of equimolar amounts of genomic DNAs from 12 Ramos clones with different vector integration sites. (C) Analysis of no-DIVAC GFP7 HIV vector (left) and ASLV vector (right) insertion sites that support substantial SHM, showing the proportion of integrations that occur within hot bins, within bins adjacent to hot bins, and within bins that meet criteria for SHM-susceptibility but not the stringent criteria required for coverage, and hence are not among the 175 high-confidence hot bins. A small fraction of insertion sites do not overlap with hot bins but none of these are in cold bins (Tables S1 and S2 ). for Total and GFP-negative populations (log scale) are shown above tracks for NIPBL, H3K4me1, superenhancers, and GRO-seq (sense and antisense above and below the line, respectively). IGL locus region is characterized by abundant integration sites in both Total and GFP-negative. 140 kb region deleted in the rearranged IGL locus (red vertical line) and IGL enhancer (red arrow) are indicated. (D) At left is shown a plot of correlation coefficients obtained by comparing the distribution of the genome integration sites of a pool of reads from all Total libraries and a single Total library (WT), and by comparing the integration sites for the same pool with samples from cells that did not undergo blasticidin selection and were collected two days post infection, thus representing GFP7 vector integration preference (no selection) in either wild-type (WT) or AID-deficient (AID-/-) cells (left chart). The data demonstrate that the correlation between selected and unselected samples is nearly as high as between two selected libraries. At right is shown a plot of how well a classification based on the integration sites from the selected pool of all Total libraries is able to predict the integration sites arising from the same three libraries analyzed in the graph to left. The unselected library integration sites are predicted nearly as well those from the selected library. into a cold TAD on chr22 (see Fig. 7A ). Each data point represents an independent measurement and the mean of the three biological replicas is indicated with a bar, with values plotted as percent of signal of input. C1, NIPBL-non-binding region (based on NIPBL ChIP-seq data). H3, histone H3; IgG, control ChIP with non-specific antibody. (D) Mean fluorescence intensity of Ramos clones with GFP7 containing the candidate enhancer elements indicated below the graphs. Since absolute fluorescence intensity values can differ between datasets gathered at different times, data from the two different experiments performed are shown on separate graphs. Independent groups of cell clones containing GFP7-ELF1e were analyzed in the two experiments. Bars represent the median of the data; each data point is a separate clone. (E) Plot showing comparison of GFP fluorescence loss and mean fluorescence intensity of independent ELF1e-GFP7
Ramos clones. Each clone was sub-cloned and the median of GFP-fluorescence loss of 12 sub-clones was plotted. (F) Enrichment analysis in the four active non-Ig enhancer elements versus the five with minimal DIVAC function. The signal for each parameter or factor (log(RPKM)) was compared between these two sets of enhancer elements (two-tailed T-test, with P-values corrected for multiple hypothesis testing). Corrected Pvalues are plotted. All data are derived from Ramos and include ChIP-seq for the indicated transcription or chromatin factors or modified histones, GRO-seq (GRO), and ATAC-seq (ATAC). NPC, nuclear pore components; PolII, total RNA Pol 2; S5P, serine-5-phosphorylated Pol2. (G) GFP-fluorescence loss of Ramos clones infected with GFP7 containing ELF1e or ZCCHC7e integrated in various integration sites compared to that of Ramos clones containing no-DIVAC-GFP7 integrated in hot TADs. Bars represent the median of the data; each dot is a separate clone.
Figure S6. NIPBL binding to truncated ELF1e, DIVAC insertion transforms a cold TAD into a SHM-susceptible genomic region Related to Figures 6 and 7 (A)
ChIP-qPCR analysis of NIPBL binding in three independent Ramos clones harboring GFP7-ELF1e-3 integrated in different cold TADs. Binding at endogenous ELF1e (endoELF1e) and truncated 250 bp vector ELF1e (ELF1e-3) was assessed using primers located within the major NIPBL peak; vector ELF1e contained two 5 bp substitutions to allow the design of primers specific for the ectopic ELF1e element. Each data point represents an independent measurement (average of duplicate technical replicas) and the mean of the two biological replicas is indicated with a bar, with values plotted as percent of signal of input. C1, a NIPBL-non-binding region (based on NIPBL ChIP-seq data). H3, histone H3; IgG, control ChIP with non-specific antibody. (B) DIVAC-trap HTISA data, both before and after superDIVAC insertion, for the chromosome 11 region into which superDIVAC was inserted. Coverage, as assessed by read numbers in the total cell population, was much higher across the genome in the chr. 22 superDIVAC insertion experiment and in the experiment with unmodified Ramos than in the experiment with the chromosome 11 DIVAC insertion. The relatively weak coverage obtained in the chromosome 11 DIVAC insertion experiment makes it difficult to appreciate the strong increase in SHM susceptibility that occurs in targeted TAD, but this is captured quantitatively in Fig. 7B . Hi-C and other data presented as in Fig. S4 . Red arrow, location of superDIVAC insertion. 
